More needed to boost Hong Kong's attractions as a clinical hub
This article was originally published in SRA
The research-based pharmaceutical industry in Hong Kong has called for improvements to the local clinical development infrastructure and systems to bolster the territory's position as an Asian hub for such work and speed up patient access to new drugs1.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.
French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics.
In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.